Evaluation of KIR3DL1/KIR3DS1 polymorphism in Behçet's disease
B Erer1,2, M Takeuchi3, D Ustek4
1Translational Genetics and Genomics Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, USA.
Genes and Immunity
|October 7, 2016
Summary
Killer immunoglobulin-like receptors (KIR) do not appear to be the primary drivers of Behçet's disease (BD) pathogenesis, despite their association with the HLA-B*51 allele. Further research into KIR gene variations is needed to fully understand their role in BD.
Area of Science:
- Immunogenetics
- Human Molecular Genetics
- Autoimmune Diseases
Background:
- Behçet's disease (BD) is a chronic inflammatory disorder with a strong genetic association with the human leukocyte antigen (HLA) allele, HLA-B*51.
- HLA-B*51 encodes ligands for killer immunoglobulin-like receptors (KIR), specifically KIR3DL1 (inhibitory) and KIR3DS1 (activating), which regulate cytotoxic cell activity.
Purpose of the Study:
- To investigate the potential contribution of KIR-regulated mechanisms to BD pathogenesis.
- To test for associations between KIR3DL1/KIR3DS1 genotypes and BD in a Turkish cohort.
Main Methods:
- Genotyping of KIR3DL1 and KIR3DS1 alleles in 1799 BD patients and 1710 healthy controls.
- HLA types were imputed from single nucleotide polymorphism genotypes.
- Analysis of KIR allele frequencies in relation to specific HLA-B types, including HLA-B*51.
Main Results:
- No significant differences in the frequencies of inhibitory KIR3DL1 or activating KIR3DS1 alleles were observed between BD cases and controls.
- KIR3DL1/KIR3DS1 allele frequencies were similar in cases and controls carrying specific HLA-B ligands, including HLA-B*51.
- The study did not find evidence that differential interactions between HLA-B*51 and KIR3DL1/KIR3DS1 are the primary pathogenic mechanism in BD.
Conclusions:
- The findings suggest that pathogenic mechanisms involving HLA-B*51 in Behçet's disease do not primarily rely on differential interactions with KIR3DL1 and KIR3DS1 receptors.
- While direct KIR3DL1/KIR3DS1 interactions may not be key, other KIR variations (e.g., sequence or copy number) cannot be excluded as contributing factors to BD pathogenesis.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
83
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
83
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
61
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61